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Background Sickle cell disease (SCD) is a common haematological dis-
order, affecting millions of people worldwide. It is most prevalent in 
malarial endemic areas in the tropics where outcomes are often poor 
due to resource constraints, resulting in most children dying before 
reaching adulthood. As increasing progress is made towards reducing 
under 5 mortality from infectious causes, non-communicable diseases 
(NCDs) including SCD have risen to the forefront of the global health 
agenda. Despite this, the global mortality burden of SCD remains poor-
ly understood. This study aimed to estimate the incidence and mortal-
ity of SCD in children under 5 years of age in order to inform policy 
and develop sustainable strategies to improve outcomes.
Methodology We performed a systematic literature search of Medline, 
EMBASE, Journals@Ovid, and Web of Science for studies on the in-
cidence and mortality of SCD in children under 5, with search dates 
set from January 1980 and July 2017. We conducted random effects 
meta-analysis to obtain pooled meta-estimates of birth prevalence 
and mortality rates globally, and for each World Health Organization 
(WHO) region.
Results 67 papers were found with relevant data. 52 contained data 
on incidence and prevalence and 15 contained data on mortality. The 
overall pooled estimate of mortality from the limited data available 
was 0.64 per 100 years of child observation (95% CI = 0.28-1.00) with 
the highest rate seen in Africa 7.3 (95% CI = 4.03-10.57). The global 
meta-estimate for the birth prevalence of homozygous sickle cell dis-
ease was 112 per 100 000 live births (95% CI = 101-123) with a birth 
prevalence in Africa of 1125 per 100 000 (95% CI = 680.43-1570.54) 
compared with 43.12 per 100 000 (95% CI = 30.31-55.92) in Europe.
Conclusion There were a number of limitations in the depth and 
breadth of available data however it is clear that both the highest prev-
alence and highest mortality of SCD is in Africa. In order to address this 
burden, there is a need for national comprehensive newborn screen-
ing to identify patients, and the development of holistic SCD care pro-
grammes to provide therapeutics and education for families and chil-
dren with SCD. This targeted funding should form part of a broader 
increased global focus on NCDs in childhood.
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Sickle cell disease (SCD) is the most common genetic haematological dis-
order, accounting for over 305000 births in 2010, with millions of peo-
ple currently affected across the globe [1,2]. Sickle haemoglobin (HbS) is 
a variant of normal adult haemoglobin, caused by a mutation in the HBB 
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gene and inherited as an autosomal recessive Mendelian trait [2]. Red blood cells (erythrocytes) with HbS 
become deformed under stress, forming a classic ‘sickle’ shape [3]. Although heterozygotes (‘sickle cell 
trait’) are usually asymptomatic, patients who have inherited HbS alleles from both parents suffer from 
Sickle Cell Anaemia (SCA), the most common and severe form of SCD (a term that technically refers 
to any condition in which the production of HbS causes symptomatology, and can result from a broad 
range of inherited HBB mutations) [3]. In patients with SCD, sickling of erythrocytes causes haemolysis, 
reduces the oxygen carrying capacity of erythrocytes, and can result in episodic microvascular occlusion 
leading to tissue ischaemia and painful ‘crises’ with serious and often life-threatening consequences [3].
The global distribution of sickle cell disease is closely linked to the natural protection against malaria af-
forded to individuals who are heterozygous for the sickle cell mutation. This selective advantage through-
out human history has resulted in the distribution of HbS mutations closely reflecting the global malaria 
incidence, focused around the tropics [4]. Unfortunately, many tropical countries do not have the neces-
sary resources required to provide the complex care required for SCD patients, and resulting outcomes 
are typically poor. While in high-income settings the current life expectancy for patients with SCA is es-
timated to be between 45-55 years of age, in low- and middle-income countries (LMICs) it is thought 
that most children die before reaching adulthood, with more than 500 children with SCD dying every 
day because of poor access to appropriate treatment [2,5,6]. This stark disparity is emphasised by cur-
rent estimates suggesting 90% of SCD occurs in LMICs, and 90% of children with SCD in LMICs die be-
fore their 5th birthday [6].
As increasing progress is made towards reducing under 5 mortality from infectious causes, non-commu-
nicable diseases (NCD) have risen to the forefront of the global health agenda. SCD is recognised as a sig-
nificant cause of NCD-related childhood mortality and has been identified as an area requiring specific 
focus in order to meet the sustainable development goals [1,6]. Despite this, the global burden of SCD 
remains poorly characterised. This study aims to estimate the incidence and mortality of SCD in children 
under 5 years of age so as to better inform policy and develop sustainable strategies to improve outcomes.
METHODS
Search strategy and selection criteria
We conducted a systematic review of the literature in accordance with the PRISMA guidelines [7]. The 
search was conducted using the following databases: Medline, EMBASE, Journals@Ovid and Web of Sci-
ence. The search terms used are detailed in Table 1. We further screened the reference lists of relevant 
papers and review papers for eligible articles. Inclusion and exclusion criteria are detailed in Table 2. 
Table 1. Search terms*
1. exp mortality/ or exp morbidity/ or exp prevalence/ or exp incidence/
2. (inciden* or prevalen* or mortality or morbidity or “case fatality”).ti,ab.
3. (burden adj2 disease*).ti,ab.
4.
exp epidemiologic methods/ or exp data collection/ or exp health surveys/ or exp morbidity/ or exp incidence/ or exp prevalence/ or exp mor-
tality/ or exp disease notification/ or exp epidemiological monitoring/
5. 1 or 2 or 3 or 4
6. exp An?emia, Sickle Cell/
7. (sickle cell adj2 (disease* or an?emi* or disorder)).ti,ab.
8. sickle h?emoglobin.ti,ab.
9. splenic sequestration.ti,ab.
10. 6 or 7 or 8 or 9
11. 5 and 10
12. limit 11 to (human and child)
13. limit 12 to yr = ”2002 - 2017”
14. remove duplicates from 13
15. limit 12 to yr = ”1980 - 2001”
16. remove duplicates from 15
17. 14 or 16
*This applies to Medline, EMBASE and Journals@Ovid.
Global burden of sickle cell disease in children under five



























































Searches were limited to between January 1980 and July 2017, and there were no publication status or 
language restrictions applied. The search was performed by two independent reviewers to minimise bias.
Data extraction
Data were extracted on study duration, location, WHO region, sample size and birth prevalence, and 
mortality from SCD. Where studies had overlap in data, the most recent study was used. Data extraction 
was also performed by two independent reviewers to minimise bias.
Definitions
Homozygous sickle cell disease was defined as being homozygous for HbSS or heterozygous with HbS-βth 
or HbSC; heterozygous sickle cell trait was defined as having the genotype HbAS. Genotype was ascer-
tained by high performance liquid chromatography or iso-electric focussing.
Quality assessment
For each full text selected, we checked for sampling (was it representative of a subnational or national 
population?), statistical analysis (was it appropriate for the prevalence or mortality estimate?), and case 
ascertainment (was it based on standard screening tests, informal interviews, or not reported?). Studies 
were graded as high (4-5), moderate (2-3), or low quality (0-1). All low quality studies were excluded 
from the review.
Statistical analysis
A random effects meta-analysis was performed on the extracted crude data to obtain pooled estimates of 
mortality and of birth prevalence for both homozygotes and heterozygotes for sickle cell. When estimat-
ing mortality, where studies did not provide mortality rate or child years of observation, child years of 
follow up was estimated by multiplying the sample population by the duration of the study. Global me-
ta-estimates were obtained as well as meta-estimates for each world region as defined by the WHO. Due 
to limited regional data, we did not conduct sub-group (sensitivity) analysis based on the assessment of 
study quality. All statistical analyses were conducted on STATA (Stata Corp V.13, Texas, USA).
RESULTS
The results of the literature search are shown in the flowchart in Figure 1. The literature search returned 
9146 records, with 67 studies selected (52 on incidence or prevalence, and 15 papers reporting on mor-
tality)
Study characteristics
From the 52 papers reporting on the incidence or prevalence of SCD, 44 papers reported on incidence 
and were prospective or retrospective cohort studies of live births. Most studies (n = 22) were from the 
Table 2. Inclusion and exclusion criteria
Inclusion criteria:
Contained data for children <5 years old
Diagnosis of sickle cell disease including homozygous sickle cell disease and heterozygous HbSC or HbS-βth
Reported on mortality, incidence or prevalence of sickle cell disease
Published between January 1980 – July 2017
Prospective or retrospective cohort studies or cross-sectional studies
Exclusion criteria:




Results not stratified by age
HbSC – hemoglobin S and C, HbSβ – hemoglobin S plus B thalassemia, HbSD – hemoglobin S and D, HbSO – hemoglobin S and O
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region of the Americas, followed by 12 from Europe, 7 from Africa, 2 from South East Asia and 1 from 
the Eastern Mediterranean Region. The duration of the study ranged from 3 months to 26 years with a 
median duration of 4 years. There were also eight cross-sectional studies reporting on sickle cell disease 
prevalence in children under five years. Five of these were from Africa, one from the East Mediterranean 
Region, one from South East Asia and one from the region of the Americas.
There were 15 studies which reported on mortality from sickle cell disease, which were prospective or 
retrospective cohort studies on groups of children with homozygous sickle cell disease. The sample size 
was between 52 and 2576, and the duration was from 6 months to 27 years with a median duration of 8 
years. There was one from African region, two from Eastern Mediterranean Region, two from European 
region and 10 from the Americas.
From all 66 studies 42 were rated as high quality and remaining 24 rated as moderate quality. All stud-
ies were conducted between 1996 and 2016. Details of all selected studies are in Tables S1, S2 and S3 in 
Online Supplementary Document.
Meta-estimates
The global meta-estimate for the birth prevalence of homozygous sickle cell disease was 111.91 per 
100 000 live births (95% CI = 100.77-123.05) (Figure 2). There were however wide disparities by re-
gion, with a birth prevalence in Africa of 1125.49 per 100 000 (95% CI = 680.43-1570.54) compared 
with 43.12 per 100 000 (95% CI = 30.31-55.92) in Europe (Figure 3).
The global meta-estimate for the birth prevalence of heterozygous sickle cell disease was 4229.72 per 
100 000 (95% CI = 3962.55-4496.90) with the highest birth prevalence in Africa: 16 121.91 per 100 000 
(95% CI = 11 853.32-20 390.49) and the lowest in Europe 803.57 (95% CI = 535.74-1071.39) (Figure 
4). There was no data available for the Eastern Mediterranean Region (Figure 5).
Figure 1. PRISMA flowchart detailing study selection.
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The overall pooled estimate of mortality from the limited data available was 0.64 per 100 years of child 
observation (95% CI = 0.28-1.00) (Figure 6). Estimates are summarised in the forest plot in Figure 2. 
There was discrepancy between regions with the lowest rate seen in Europe 0.11 (95% CI = -0.24-0.46) 
and the highest rate seen in Africa 7.3 (95% CI = 4.03-10.57) (Figure 7).
DISCUSSION
From our pooled meta-estimates, we found the overall mortality rate to be 0.64 per 100 years of child 
observation with the highest rate in Africa at 7.3 per 100 years of observation. The confidence in these 
Figure 2. Pooled birth prevalence (per 100 000 live births) of sickle cell disease homozygotes glob-
ally and by world regions.
Figure 3. Distribution of birth prevalence (per 
100 000 live births) of sickle cell disease homozy-
gotes by world regions. Note: The boxes represent 
the interquartile range of birth prevalence where 
the middle 50% (25-75%) of data are distributed; 
the bars represent birth prevalence outside the mid-
dle 50% (<25% or >75%); the dots represent spe-
cific birth prevalence which were a lot higher than 
normally observed (outliers) and the lower, middle 
and upper horizontal lines represent the minimum, 
median and maximum birth prevalence (excluding 
outliers), respectively.
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Figure 4. Pooled birth prevalence (per 100 000 live births) of sickle cell disease heterozygotes by 
world regions.
Figure 5. Distribution of birth prevalence (per 
100 000 live births) of sickle cell disease hetero-
zygotes by world regions. Note: The boxes rep-
resent the interquartile range of birth prevalence 
where the middle 50% (25-75%) of data are 
distributed; the bars represent birth prevalence 
outside the middle 50% (<25% or >75%); the 
dots represent specific birth prevalence which 
were a lot higher than normally observed (outli-
ers) and the lower, middle and upper horizon-
tal lines represent the minimum, median and 
maximum birth prevalence (excluding outliers), 
respectively.
figures however is low due to limited available data. We estimated the global birth prevalence of homo-
zygous SCD to be 0.11%. In 2015, this would amount to about 150 000 births with SCD. This is much 
lower than the estimates reported by Piel and colleagues [2], with 305800 newborns with sickle cell ane-
mia estimated in 2010. Although the study made several assumptions which could have resulted in their 
higher estimates, the lack of data on SCD from several African countries, where the prevalence and mor-
tality from SCD are presumed to be higher, could have affected our estimates. For example, in the Afri-
can Region (with only seven studies), the birth prevalence was ten times higher at 1.1% compared to our 
overall pooled estimate of 0.11%. Indeed, the higher SCD estimates are expected due to the relationship 
between sickle cell trait and malaria endemic regions. This presents major concerns as many African na-
tions lack the resources to provide care and follow-up [5]. In addition, malaria precipitates sickling crises 
and is thought to be the most common cause of childhood mortality in patients with SCD [8].
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Figure 6. Pooled mortality rate (per 100 child-years of observation) due to sickle cell disease 
across world regions.
Figure 7. Distribution of sickle-cell disease mor-
tality (per 100 child-years of observation) over 
world regions. Note: The boxes represent the in-
terquartile range of mortality rate where the mid-
dle 50% (25-75%) of data are distributed; the 
bars represent mortality rate outside the middle 
50% (< 25% or > 75%); the dots represent spe-
cific mortality rate which were a lot higher than 
normally observed (outliers) and the lower, mid-
dle and upper horizontal lines represent the min-
imum, median and maximum mortality rate (ex-
cluding outliers), respectively.
Limitations
There were several limitations in data contributing to our estimates. There is a paucity of mortality data 
available for children under 5 globally, likely a reflection of the fact that in HICs under 5 mortality from 
SCD is now very low whereas in LMICs many children with SCD die before diagnosis [9]. Only five of 
the studies included data collected in the last decade, meaning even the data from HIC is likely to be un-
reflective of the current situation, where SCD is now better understood and there is a greater evidence for 
treatment options. In LMICs there was only one study in Tanzania reporting on mortality and as this is a 
single centre study in a sickle cell treatment unit, the generalizability of the results is likely to be limited 
[10]. Furthermore, much mortality data was poorly characterised and did not provide mortality rate or 
child years of observation. This meant that in calculating the meta-estimates often the only option was to 
Wastnedge et al.



























































multiply the sample population by the duration of study to estimate child years of follow up, resulting in 
mortality figures that are likely under-estimates.
Most incidence and prevalence data were from regions with the lowest incidence of SCD – North Amer-
ica and Europe – in countries where there are reliable birth registries and mandatory neonatal screening. 
Only six studies from the African region could be included in the meta-estimate for birth prevalence and 
there was wide variation in estimates from these countries. Because there are few comprehensive nation-
al screening programmes in LMICs, the quality of data from these regions was lower, often coming from 
single centre studies or cross-sectional studies. The lack of national birth registries also meant that much 
of the data from LMICs, particularly in the African region, only captured births within health centre/hos-
pitals, resulting in selection bias as in Sub-Saharan Africa only half of births occur within health care fa-
cilities [11]. Therefore, while we can have reasonable confidence in the meta-estimates of birth prevalence 
from Europe and America, the data limitations from the other regions mean that our figures are likely to 
be under-estimates of the disease burden.
Findings in context
It is clear from our results that SCD is an important contributor to under 5 mortality in LMICs, particu-
larly sub-Saharan Africa. The wide discrepancy between mortality in these settings compared with HIC 
suggests that much of this mortality is largely preventable. There is considerable evidence for comprehen-
sive SCD care programmes as a way to improve outcomes for children with SCD, providing penicillin and 
malarial chemoprophylaxis as well as family education [5,12,13]. There has been some success piloting 
such programmes in LMICs, for example a trial of holistic family education in Benin showed a significant 
improvement in general health of children with SCD and a marked reduction in acute SCD events [12]. 
A similar program in Nigeria showed a reduction in mortality from 20.6% to 0.6%, as well as markedly 
reduced hospital admissions and transfusion requirements [13]. Due to the added risk of malaria in trop-
ical regions, any such programmes must be combined with adequate malaria treatment strategies and all 
children with SCD should be on lifelong malarial chemoprophylaxis [8]. Hopefully lessons learned from 
these programmes can be used to increase the coverage of these much-needed interventions [1], howev-
er the difficulty is in securing sustainable funding to continue such programmes, particularly in a current 
political climate where NCDs are under-recognised and under-funded by the international community [5].
Enhanced diagnostics to enable early case-identification will also be essential in improving SCD outcomes. 
Currently neonatal screening is not widely available in many LMICs and many children die having nev-
er been diagnosed [14]. One important step in tackling SCD, therefore, could be the introduction of na-
tional comprehensive newborn screening programmes. Laboratory and staffing constraints make this a 
challenging task to accomplish, particularly as currently the diagnosis of SCD relies on relatively sophis-
ticated techniques of high performance liquid chromatography or iso-electric focussing [1]. There has 
been some progress in the development of a rapid diagnostic test for SCD and if this could be widely and 
cheaply available, it could be powerful in early detection of cases [6,15].
CONCLUSION
SCD is an under-recognised and under-funded cause of under 5 mortality, particularly in Africa. There 
are several well recognised and well evidenced ways to improve outcomes and the development of in-
tegrated treatment pathways for SCD sufferers would be a powerful way to tackle this excess mortality 
and morbidity. Comprehensive newborn screening programmes are a crucial part of attaining this and 
this may become more achievable with the promise of a rapid-diagnostic test on the horizon. The cur-
rent evidence base is limited and there is a need for large scale prospective cohort studies to accurately 
assess the SCD burden. For any headway to be made in tackling SCD, funding needs to be repriori-
tised to bring NCDs to the fore, particularly genetic disease such as this one which have received little 
global investment to date.
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